Merck & Co., Inc. (MRK)
NYSE: MRK · Real-Time Price · USD
129.56
0.00 (0.00%)
At close: Jul 2, 2026, 4:00 PM EDT
129.00
-0.56 (-0.43%)
Pre-market: Jul 6, 2026, 8:06 AM EDT
Merck & Co. Employees
Merck & Co. had 75,000 employees as of December 31, 2025. The number of employees did not change compared to the previous year.
Employees
75,000
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$876,907
Profits / Employee
$119,133
Market Cap
319.99B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 75,000 | 0 | - |
| Dec 31, 2024 | 75,000 | 3,000 | 4.17% |
| Dec 31, 2023 | 72,000 | 3,000 | 4.35% |
| Dec 31, 2022 | 69,000 | 1,000 | 1.47% |
| Dec 31, 2021 | 68,000 | -6,000 | -8.11% |
| Dec 31, 2020 | 74,000 | 3,000 | 4.23% |
| Dec 31, 2019 | 71,000 | 2,000 | 2.90% |
| Dec 31, 2018 | 69,000 | 0 | - |
| Dec 31, 2017 | 69,000 | 1,000 | 1.47% |
| Dec 31, 2016 | 68,000 | 0 | - |
| Dec 31, 2015 | 68,000 | -2,000 | -2.86% |
| Dec 31, 2014 | 70,000 | -6,000 | -7.89% |
| Dec 31, 2013 | 76,000 | -7,000 | -8.43% |
| Dec 31, 2012 | 83,000 | -3,000 | -3.49% |
| Dec 31, 2011 | 86,000 | -8,000 | -8.51% |
| Dec 31, 2010 | 94,000 | -6,000 | -6.00% |
| Dec 31, 2009 | 100,000 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Johnson & Johnson | 138,200 |
| AstraZeneca | 95,100 |
| Novartis AG | 75,267 |
| Pfizer | 75,000 |
| Sanofi | 74,846 |
| Novo Nordisk | 69,505 |
| GSK plc | 66,841 |
| AbbVie | 57,000 |
MRK News
- 5 days ago - Merck to Hold Second-Quarter 2026 Sales and Earnings Conference Call Aug. 4 - Business Wire
- 6 days ago - US House committee opens investigation into Merck, AbbVie China drug trials - Reuters
- 6 days ago - Merck & Company (MRK) Price Forecast: Can Momentum Drive New Highs? - FXEmpire
- 7 days ago - Merck Announces New Agreement with ADAP Crisis Task Force to Improve Access and Care for People Living with HIV - Business Wire
- 11 days ago - FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), each with Trodelvy® (sacituzumab govitecan-hziy) as First-Line Treatment of PD-L1+ (CPS ≥10) Advanced Triple-Negative Breast Cancer (TNBC) - Business Wire
- 12 days ago - European Commission Approves KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as First PD-1 Inhibitor Plus Antibody-Drug Conjugate Regimen for Adults With Cisplatin-Ineligible Resectable Muscle-Invasive Bladder Cancer - Business Wire
- 12 days ago - Merck and Mae Partner to Expand Doula Workforce and Address Maternal Health Disparities in High-Risk U.S. Markets - Business Wire
- 14 days ago - Merck's bowel disease drug meets main goal in late-stage trial - Reuters